1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. WuXi AppTec Co., Ltd.
  6. News
  7. Summary
    603259   CNE1000031K4

WUXI APPTEC CO., LTD.

(603259)
  Report
End-of-day quote Shanghai Stock Exchange  -  2022-08-17
90.79 CNY   -1.25%
08/15WuXi ATU Announces Licensing Agreement with Janssen for TESSA Technology
AQ
08/09DELIVERING ON THE PROMISE OF NEW THERAPIES FOR RARE DISEASES : An Interview with Ralph Laufer, CSO of Lysogene
PU
08/01DELIVERING THE PROMISE OF NEW MODALITIES : An Interview with Mark Frohlich, CEO, Indapta Therapeutics
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about WUXI APPTEC CO., LTD.
08/15WuXi ATU Announces Licensing Agreement with Janssen for TESSA Technology
AQ
08/09DELIVERING ON THE PROMISE OF NEW THE : An Interview with Ralph Laufer, CSO of Lysogene
PU
08/01DELIVERING THE PROMISE OF NEW MODALI : An Interview with Mark Frohlich, CEO, Indapta Thera..
PU
07/29UBS Adjusts Wuxi Apptec's Price Target to HK$175 From HK$173, Keeps at Buy
MT
07/27WUXI APPTEC : DDSU - 2022 Investor Day
PU
07/27WUXI APPTEC : ATU - 2022 Investor Day
PU
07/27WUXI APPTEC : Biology - 2022 Investor Day
PU
07/27WUXI APPTEC : Testing - 2022 Investor Day
PU
07/27WUXI APPTEC : Chemistry - 2022 Investor Day
PU
07/27WUXI APPTEC : Industry Trend and Company Strategy - 2022 Investor Day
PU
07/27WUXI APPTEC : Financial Performance - 2022 Investor Day
PU
07/27Nomura Adjusts Wuxi Apptec's Price Target to HK$171.11 From HK$181.12, Keeps at Buy
MT
07/27Nomura Adjusts Wuxi Apptec's Price Target to 147.15 Yuan From 148.52 Yuan, Keeps at Buy
MT
07/26WuXi AppTec's H1 Profit Jumps 73%; Shares Fall 4% in Shanghai
MT
07/26WUXI APPTEC : 2022 Interim Results Presentation
PU
More most relevant news
All news about WUXI APPTEC CO., LTD.
08/15WuXi ATU Announces Licensing Agreement with Janssen for TESSA Technology
AQ
08/09DELIVERING ON THE PROMISE OF NEW THE : An Interview with Ralph Laufer, CSO of Lysogene
PU
08/01DELIVERING THE PROMISE OF NEW MODALI : An Interview with Mark Frohlich, CEO, Indapta Thera..
PU
07/29UBS Adjusts Wuxi Apptec's Price Target to HK$175 From HK$173, Keeps at Buy
MT
07/27WUXI APPTEC : DDSU - 2022 Investor Day
PU
07/27WUXI APPTEC : ATU - 2022 Investor Day
PU
07/27WUXI APPTEC : Biology - 2022 Investor Day
PU
07/27WUXI APPTEC : Testing - 2022 Investor Day
PU
07/27WUXI APPTEC : Chemistry - 2022 Investor Day
PU
07/27WUXI APPTEC : Industry Trend and Company Strategy - 2022 Investor Day
PU
More news
News in other languages on WUXI APPTEC CO., LTD.
07/29Las acciones chinas caen; los beneficios podrían impulsar el mercado en agosto -- Marke..
07/26Le bénéfice de WuXi AppTec au premier semestre fait un bond de 73 % ; les actions chute..
07/26WuXi AppTec Co., Ltd. annonce ses résultats pour le semestre clos le 30 juin 2022
07/26WuXi AppTec Co., Ltd. fournit des prévisions de revenus pour l'année 2022
07/22Wuxi Apptec réalise 2,6 millions de dollars de recettes au premier semestre
07/22Les entreprises chinoises Wuxi AppTec et Wuxi Biologics vont investir chacune 1,4 milli..
07/19WuXi AppTec prévoit de construire un nouveau site de R&D et de fabrication à Singapour
07/12Sirona Biochem annonce le début de l'essai clinique d'un composé anti-vieillissement et..
07/12WuXi AppTec enregistre une hausse de son bénéfice et de son chiffre d'affaires au premi..
06/22Sirona Biochem confie à WuXi AppTec la fabrication d'un composé anti-âge destiné à un e..
More news
Analyst Recommendations on WUXI APPTEC CO., LTD.
07/29UBS Adjusts Wuxi Apptec's Price Target to HK$175 From HK$173, Keeps at Buy
MT
07/27Nomura Adjusts Wuxi Apptec's Price Target to HK$171.11 From HK$181.12, Keeps at Buy
MT
07/27Nomura Adjusts Wuxi Apptec's Price Target to 147.15 Yuan From 148.52 Yuan, Keeps at Buy
MT
04/28UBS Adjusts WuXi AppTec's Price Target to HK$173 From HK$192, Keeps at Buy
MT
02/17Nomura Adjusts Wuxi Apptec's Price Target to HK$181.12 From HK$208.86, Keeps at Buy
MT
More recommendations
Press releases
08/15WuXi ATU Announces Licensing Agreement with Janssen for TESSA Technology
AQ
08/09DELIVERING ON THE PROMISE OF NEW THE : An Interview with Ralph Laufer, CSO of Lysogene
PU
08/01DELIVERING THE PROMISE OF NEW MODALI : An Interview with Mark Frohlich, CEO, Indapta Thera..
PU
07/27WUXI APPTEC : DDSU - 2022 Investor Day
PU
07/27WUXI APPTEC : ATU - 2022 Investor Day
PU
More press releases
Upcoming event on WUXI APPTEC CO., LTD.